The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Interleukin-6, Interleukin-10, and Vascular Endothelial Growth Factor in Metastatic Renal Cell Carcinoma: Prognostic Value of Interleukin-6—From the Groupe Français d'Immunothérapie
Abstract
Purpose: Few clinical prognostic factors have been identified for patients with metastatic renal cell carcinoma (MRCC), and no biomarker is known in this disease. Several endogenous cytokines have demonstrated interesting and significant correlations with survival in these patients. Our objective was to analyze the prognostic value of circulating vascular endothelial growth factor (VEGF), interleukin-10 (IL-10), and interleukin-6 (IL-6). Patients and Methods: Serum levels of IL-6, IL-10, and VEGF were measured in patients with MRCC. Their prognostic value for response to treatment and progression-free and overall survival was evaluated. Pretreatment samples were obtained from 138 patients of a large randomized multicentric trial. Endogenous cytokine levels were determined using immunoassays. Univariate and multivariate analyses were performed to evaluate the prognostic value of each factor further controlled by an internal validation test. Threshold values for serum IL-6 and VEGF were determined using the quartile method. Results: Serum IL-6 was detectable in 70% of the patients. IL-10 and VEGF were elevated in 8% and 71% of the patients, respectively. None of these circulating factors was correlated with response to treatment. IL-10 was not significantly correlated with progression-free or overall survival. Despite significant correlation with survival, VEGF was not an independent prognostic factor in the multivariate analysis. Finally, IL-6 was significantly correlated with progression-free survival and overall survival, and has prognostic value for overall survival. Conclusion: Circulating IL-6 level appears to be an important independent prognostic factor in patients with MRCC; if confirmed in further studies, it could be considered for treatment decisions in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Menetrier-Caux, C., Montmain, G., Dieu, M. C., Bain, C., Favrot, M. C., Caux, C., & Blay, J. Y. (1998) · Blood · doi:10.1182/blood.v92.12.4778 · Cited by 590
Self-citation
Cited by
Ray-Coquard, I., Cropet, C., Van Glabbeke, M., Sebban, C., Le Cesne, A., Judson, I., Tredan, O., Verweij, J., Biron, P., Labidi, I., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3845 · Cited by 784
Self-citationInterleukin-6 signaling pathway in targeted therapy for cancer
Guo, Y., Xu, F., Lu, T., Duan, Z., & Zhang, Z. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.04.007 · Cited by 686
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers
Yao, X., Huang, J., Zhong, H., Shen, N., Faggioni, R., Fung, M., & Yao, Y. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.004 · Cited by 664
Cytokines and their relationship to the symptoms and outcome of cancer
Seruga, B., Zhang, H., Bernstein, L. J., & Tannock, I. F. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2507 · Cited by 652
Immunotherapy for advanced renal cell cancer
Coppin, C., Porzsolt, F., Autenrieth, M., Kumpf, J., Coldman, A., & Wilt, T. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001425.pub2 · Cited by 589
RetractedInterleukin-10 and the immune response against cancer: a counterpoint
Mocellin, S., Marincola, F. M., & Young, H. A. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0705358 · Cited by 402
Interleukin‐6 and its receptor in cancer: Implications for Translational Therapeutics
Hong, D. S., Angelo, L. S., & Kurzrock, R. (2007) · Cancer · doi:10.1002/cncr.22999 · Cited by 370
“High circulating levels of IL-6 correlate with the presence of metastatic disease.(143) High IL-6 levels predict a poor prognosis, and analysis has confirmed that there is a linear correlation between stage, grade, and tumor size and IL-6 levels.”
BackgroundPrognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review
Sun, M., Shariat, S. F., Cheng, C., Ficarra, V., Murai, M., Oudard, S., Pantuck, A. J., Zigeuner, R., & Karakiewicz, P. I. (2011) · European Urology · doi:10.1016/j.eururo.2011.06.041 · Cited by 325
Tran, H. T., Liu, Y., Zurita, A. J., Lin, Y., Baker-Neblett, K. L., Martin, A.-M., Figlin, R. A., Hutson, T. E., Sternberg, C. N., Amado, R. G., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70241-3 · Cited by 261
Rini, B., Goddard, A., Knezevic, D., Maddala, T., Zhou, M., Aydin, H., Campbell, S., Elson, P., Koscielny, S., Lopatin, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70167-1 · Cited by 254
Self-citationLippitz, B. E., & Harris, R. A. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1093722 · Cited by 248
Rossi, J.-F., Négrier, S., James, N. D., Kocak, I., Hawkins, R., Davis, H., Prabhakar, U., Qin, X., Mulders, P., & Berns, B. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605872 · Cited by 166
Capone, F., Guerriero, E., Sorice, A., Colonna, G., Ciliberto, G., & Costantini, S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3064643 · Cited by 38
“This study demonstrated that serum levels of IL-5, IL-12, IL-6, and VEGFA contributed to prognostic evaluation in mRCC and to identify patients with 20% 5-year OS [47].”
BackgroundResultInfluential
Metadata
- Authors
- Negrier, S., Perol, D., Menetrier-Caux, C., Escudier, B., Pallardy, M., Ravaud, A., Douillard, J.-Y., Chevreau, C., Lasset, C., & Blay, J.-Y.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-06-15
- Volume
- 22
- Issue
- 12
- Pages
- 2371-2378
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2146853858
- Cited by
- 176
- References
- 1
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.